IL207127A0 - Aldh-2 inhibitors in the treatment of addiction - Google Patents
Aldh-2 inhibitors in the treatment of addictionInfo
- Publication number
- IL207127A0 IL207127A0 IL207127A IL20712710A IL207127A0 IL 207127 A0 IL207127 A0 IL 207127A0 IL 207127 A IL207127 A IL 207127A IL 20712710 A IL20712710 A IL 20712710A IL 207127 A0 IL207127 A0 IL 207127A0
- Authority
- IL
- Israel
- Prior art keywords
- aldh
- addiction
- inhibitors
- treatment
- Prior art date
Links
- 206010012335 Dependence Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/051862 WO2009094028A1 (en) | 2008-01-24 | 2008-01-24 | Aldh-2 inhibitors in the treatment of addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL207127A0 true IL207127A0 (en) | 2010-12-30 |
Family
ID=39731733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL207127A IL207127A0 (en) | 2008-01-24 | 2010-07-21 | Aldh-2 inhibitors in the treatment of addiction |
Country Status (13)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102161648A (zh) * | 2011-02-18 | 2011-08-24 | 中国药科大学 | 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途 |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| AR087700A1 (es) | 2011-08-30 | 2014-04-09 | Gilead Sciences Inc | Inhibidores de aldh-2 en el tratamiento de adicciones |
| CA3077606A1 (en) * | 2017-10-16 | 2019-04-25 | Amygdala Neurosciences, Inc. | Combination therapy for preventing addiction |
| CN108276374B (zh) * | 2018-03-29 | 2020-01-31 | 天津科技大学 | 黄酮类芳香化酶抑制剂及其制备方法与应用 |
| CN110922394B (zh) * | 2019-11-21 | 2021-04-06 | 中国科学院宁波材料技术与工程研究所 | 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用 |
| EP4532016A2 (en) * | 2022-05-31 | 2025-04-09 | University of Maryland, Baltimore | Aldh2 inhibitors and methods of use thereof |
| WO2023244574A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| WO2023244563A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU162377B (enrdf_load_stackoverflow) * | 1970-05-27 | 1973-02-28 | ||
| US4166862A (en) * | 1971-05-25 | 1979-09-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Animal feed containing anabolic isoflavones |
| GB8626344D0 (en) * | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
| US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| EP1077697B1 (en) * | 1998-05-12 | 2006-07-19 | The Endowment For Research In Human Biology, Inc. | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| EP1524974A4 (en) * | 2001-05-04 | 2007-12-05 | Paratek Pharm Innc | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE |
| AUPR957001A0 (en) * | 2001-12-19 | 2002-01-24 | Novogen Research Pty Ltd | Isoflavone conjugates, derivatives thereof and therapeutic methods involving same |
| NZ537366A (en) * | 2002-06-27 | 2007-12-21 | Endowment For Res In Human Bio | Compounds useful for the inhibition of ALDH |
| CA2571421A1 (en) * | 2004-06-24 | 2006-01-05 | Nicholas Valiante | Compounds for immunopotentiation |
| PL377180A1 (pl) * | 2005-09-21 | 2007-04-02 | Instytut Farmaceutyczny | Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz |
| EP2046769A2 (en) * | 2006-07-27 | 2009-04-15 | Cv Therapeutics, Inc. | Aldh-2 inhibitors in the treatment of addiction |
| JP2011503095A (ja) * | 2007-11-06 | 2011-01-27 | ギリアード・パロ・アルト・インコーポレイテッド | 精神障害の処置におけるａｌｄｈ−２インヒビター |
-
2008
- 2008-01-24 MX MX2010008111A patent/MX2010008111A/es not_active Application Discontinuation
- 2008-01-24 BR BRPI0822129-4A patent/BRPI0822129A2/pt not_active IP Right Cessation
- 2008-01-24 WO PCT/US2008/051862 patent/WO2009094028A1/en active Application Filing
- 2008-01-24 AU AU2008348372A patent/AU2008348372A1/en not_active Abandoned
- 2008-01-24 JP JP2010544284A patent/JP2011510072A/ja active Pending
- 2008-01-24 CA CA2712750A patent/CA2712750A1/en not_active Abandoned
- 2008-01-24 EP EP08713963A patent/EP2254878A1/en not_active Withdrawn
- 2008-01-24 CN CN200880125439XA patent/CN101925590A/zh active Pending
- 2008-01-24 KR KR1020107016579A patent/KR20100130589A/ko not_active Withdrawn
-
2010
- 2010-07-02 ZA ZA2010/04671A patent/ZA201004671B/en unknown
- 2010-07-21 IL IL207127A patent/IL207127A0/en unknown
- 2010-08-23 MA MA33106A patent/MA32095B1/fr unknown
- 2010-08-23 EC EC2010010417A patent/ECSP10010417A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0822129A2 (pt) | 2015-06-23 |
| AU2008348372A1 (en) | 2009-07-30 |
| CN101925590A (zh) | 2010-12-22 |
| MX2010008111A (es) | 2010-11-30 |
| ECSP10010417A (es) | 2010-11-30 |
| KR20100130589A (ko) | 2010-12-13 |
| CA2712750A1 (en) | 2009-07-30 |
| MA32095B1 (fr) | 2011-02-01 |
| JP2011510072A (ja) | 2011-03-31 |
| EP2254878A1 (en) | 2010-12-01 |
| ZA201004671B (en) | 2011-03-30 |
| WO2009094028A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL195400A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
| IL230683A0 (en) | dpp-iv inhibitors for use in the treatment of nafld | |
| IL208354A0 (en) | Methods of treatment | |
| IL213619A0 (en) | Treatment | |
| IL212348A0 (en) | Treatment method | |
| EP2200977A4 (en) | F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS | |
| IL213547A0 (en) | Compounds and methods of use | |
| EP2340244A4 (en) | COMPOUNDS AND APPLICATION PROCEDURES | |
| EP2308884A4 (en) | PROCESS FOR THE PREPARATION OF HETEROSUBSTITUTED ALKYLHALOHYDROSILANE AND ITS USE | |
| IL209754A0 (en) | Diazacarbazoles and methods of use | |
| GB0802116D0 (en) | Treatment | |
| GB0822011D0 (en) | Treatment | |
| GB2475018B (en) | Water treatment methods | |
| IL207127A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
| GB0819280D0 (en) | Imgaing and radiotherapy methods | |
| IL210097A0 (en) | Compositions and methods for treating unfluenza | |
| IL209548A0 (en) | Diazacarbazoles and methods of use | |
| GB0807018D0 (en) | Antibodies and treatment | |
| IL217966A0 (en) | Hsl inhibitors useful in the treatment of diabetes | |
| GB0811992D0 (en) | Treatment | |
| IL208611A0 (en) | Device and process for the formation of microdepositions | |
| GB0918601D0 (en) | Decahydro-1H-Indenoquinolinone and decahydro-3H-cyclopenaphenanthridinone CYP17 inhibitors | |
| EP2164494A4 (en) | Methods of Treatment | |
| EP2512504A4 (en) | COMPOSITION AND THERAPEUTIC METHOD | |
| IL230746A0 (en) | 2-aldh inhibitors in the treatment of addiction |